“Users have long desired a small, discreet, and fully featured in-the-ear hearing aid. Through our innovative RightFit™ ...

Valneva retransmettra aujourd’hui en direct la conférence téléphonique sur les résultats financiers du premier semestre 2025 à 15h00 CEST (9h00 EDT). Cette retransmission sera disponible sur le site ...

Europe is home to the majority of Sandoz operations, and this partnership is expected to meet nearly 90% of current electricity demand across the company’s European sites. Under the agreement, Sandoz ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Ianalumab, ...

Männedorf, Switzerland, August 12, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today announced its financial results for the first half of 2025 and confirmed its outlook for full year 2025.

The notes will be general unsecured, senior obligations of Ligand and will accrue interest payable semiannually in arrears on April 1 and October 1 of each year, beginning on April 1, 2026 at a rate ...

Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its ...

Gross profit was $14.1 million in the second quarter of 2025, or 69.8% of revenue, compared to $11.1 million, or 68.8% of revenue, in the same period in 2024. The increase in gross margin was ...

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today ...

(2) Legal settlements, net of insurance proceeds, represents the net impact of legal settlements reached in the period. For the six months ended June 30, 2025, amount primarily includes the net impact ...

Chemotherapy and radiation therapy remain standard for locally advanced and metastatic cervical cancer. However, they often ...

Inventiva est une société cotée sur le compartiment B du marché réglementé d'Euronext Paris (symbole : IVA - ISIN : FR0013233012) et sur le marché Nasdaq Global Market aux Etats-Unis (symbole : IVA).